Controlled Substances and Regulatory Law

Ansell Grimm & Aaron PC partner Josh Bauchner recently wrote a guest column for Cannabis Insider addressing issues surrounding the appeal of New Jersey’s 2019 Request for Applications to open medical marijuana facilities. The column, in full, appears below: In the last issue of Cannabis Insider, a guest columnist purported

According to a recent report in the NJCannabis Insider (subscription required) applicants from the 2019 Request for Applications for medical cannabis licensing denied due to corruption of their online applications continue to await their day in court. Josh Bauchner, an attorney with Ansell Grimm & Aaron PC representing several clients

NJ Cannabis Insider reported on its largest panel and networking event, NJ Cannabis Insider Live: The Road to Legalization held on Tuesday, March 10, 2020, at the New Jersey Convention and Expo Center in Edison. The event featured regulators, industry power players, entrepreneurs and professionals. Among the speakers highlighted were Joshua

New Jersey recently launched a hemp program in accord with the federal Hemp Farming Act of 2018  which removed hemp (generally defined as cannabis with less than 0.3% THC) from Schedule I of the  Controlled Substances Act instead treating it as an ordinary agricultural commodity. Its provisions were incorporated into the 2018 United States Farm bill that became law

Event: 2nd Annual Cannabis Symposium Date: Wednesday, March 18, 2020 Location: Webcast Details: Ansell Grimm & Aaron shareholder, Joshua S. Bauchner will present at the 2nd Annual Cannabis Symposium presented by the New Jersey Institute for Continuing Legal Education (NJICLE) in cooperation with the New Jersey State Bar Association (NJSBA) Cannabis